Inhibition of DNA repair pathways in tumor cells sensitized by chemotherapeutic agents

The phrase "Inhibition of DNA repair pathways in tumor cells sensitized by chemotherapeutic agents" does not refer to a single molecule or receptor but rather describes a **therapeutic strategy**. This approach involves blocking key proteins or enzymatic activities within cellular mechanisms that detect and fix damaged DNA. Tumor cells often rely on these pathways for survival after exposure to chemotherapy or radiation—which induce lethal levels of genetic damage. By inhibiting proteins such as **PARP**, **ATR**, **ATM**, or **DNA-PK**, cancer therapies can prevent effective repair in malignant cells, thereby increasing their sensitivity ("sensitization") to standard treatments and promoting cell death. Several drugs targeting these processes are approved or under investigation; however, this entry is not itself a canonical target but an umbrella term describing the pharmacological blockade of one or more components within the broader network known as the "DNA damage response" or "DNA repair machinery". Because this entry refers to a process rather than an individual protein/gene/receptor/enzyme/transporter/etc., it should be flagged as incorrect if used as a canonical target name. For structured data purposes, each specific protein targeted—such as Poly(ADP-ribose) polymerase 1 (**PARP1**), Ataxia telangiectasia mutated (**ATM**), Ataxia telangiectasia and Rad3-related protein (**ATR**), or others—should be listed individually with their own attributes. Targeting the cellular machinery responsible for repairing chemotherapy-induced genetic lesions has become an important strategy in oncology drug development. The most common approach involves using small-molecule inhibitors against key enzymes like PARP1/2, ATR kinase, ATM kinase, and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). These interventions exploit vulnerabilities in tumors with defective homologous recombination—such as those harboring BRCA mutations—and can overcome resistance mechanisms while also introducing new safety challenges related to impaired genome maintenance. If you need information about any specific enzyme/protein involved in this process—for example "Poly(ADP-ribose) polymerase 1"—please specify so that structured details can be provided at that level.

Other names

DNA repair pathway inhibitionDNA damage response inhibitionDDR pathway inhibitionSensitization of tumor cells to chemotherapy via DNA repair blockade

Inhibition of specific enzymes involved in the detection and/or repair of damaged DNA strands leads to accumulation of unrepaired lesions and increased cancer cell death when combined with chemotherapeutic agents